Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Research Article 2025CC BY-NCFree full text · non-commercial reuse

Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program.

Anup D. Patel, Jerzy P. Szaflarski, Paul D. Lyons, Michael Boffa, Teresa Greco, Timothy B. Saurer +3 more

Objective Cannabidiol (CBD) treatment was associated with long-term seizure reduction in patients with various treatment-resistant epilepsies who participated in the CBD Expanded Access Program. A phase 3 trial showed CBD effectively treats tuberous sclerosis complex (TSC)-associated seizures, which are primarily of focal origin. However, the effectiveness of CBD in non-TSC focal epilepsies is not well reported. H…

Epilepsia Europe PMC

Open article record in new tab ↗

Research Article 2022CC BY-NCFree full text · non-commercial reuse

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.

Joyce Y Wu, Hannah R Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin M Roberts +3 more

Objective To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (TSC). Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epid…

Epilepsia